Antibe Therapeutics Inc.

TSX:ATE Voorraadrapport

Marktkapitalisatie: CA$15.6m

Antibe Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Dan Legault

Algemeen directeur

CA$784.9k

Totale compensatie

Percentage CEO-salaris65.6%
Dienstverband CEO15yrs
Eigendom CEO2.1%
Management gemiddelde ambtstermijn4.1yrs
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Recent updates

Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

Dec 15
Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Mar 20
We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

Oct 16
Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

Feb 11
Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Jan 07
We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)

Jul 31
Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)

Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021

Jul 29
Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021

Analyse CEO-vergoeding

Hoe is Dan Legault's beloning veranderd ten opzichte van Antibe Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Dec 31 2023n/an/a

-CA$18m

Sep 30 2023n/an/a

-CA$18m

Jun 30 2023n/an/a

-CA$19m

Mar 31 2023CA$785kCA$515k

-CA$19m

Dec 31 2022n/an/a

-CA$21m

Sep 30 2022n/an/a

-CA$22m

Jun 30 2022n/an/a

-CA$24m

Mar 31 2022CA$715kCA$443k

-CA$25m

Dec 31 2021n/an/a

-CA$26m

Sep 30 2021n/an/a

-CA$26m

Jun 30 2021n/an/a

-CA$25m

Mar 31 2021CA$3mCA$357k

-CA$24m

Dec 31 2020n/an/a

-CA$25m

Sep 30 2020n/an/a

-CA$23m

Jun 30 2020n/an/a

-CA$21m

Mar 31 2020CA$1mCA$311k

-CA$19m

Dec 31 2019n/an/a

-CA$17m

Sep 30 2019n/an/a

-CA$16m

Jun 30 2019n/an/a

-CA$13m

Mar 31 2019CA$2mCA$311k

-CA$13m

Dec 31 2018n/an/a

-CA$11m

Sep 30 2018n/an/a

-CA$9m

Jun 30 2018n/an/a

-CA$8m

Mar 31 2018CA$273kCA$273k

-CA$7m

Compensatie versus markt: De totale vergoeding ($USD 576.21K ) Dan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 172.18K ).

Compensatie versus inkomsten: De vergoeding van Dan is gestegen terwijl het bedrijf verliesgevend is.

CEO

Dan Legault (65 yo)

15yrs

Tenure

CA$784,861

Compensatie

Mr. Daniel Marcel Legault, also known as Dan, J.D., L.L.B, served as the Independent Chairman at Klinik Health Ventures Corp. and served as its Independent Director since April 17, 2019 and served as its P...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Daniel Legault
President15yrsCA$784.86k2.13%
CA$ 333.2k
Alain Wilson
Chief Financial Officer8.4yrsCA$219.93k0.13%
CA$ 20.3k
Scott Curtis
Chief Operating Officer1.8yrsCA$316.21k0.22%
CA$ 33.9k
David Vaughan
Chief Development Officerno dataCA$423.61k0.050%
CA$ 7.9k
Joseph Stauffer
Chief Medical Officer4.1yrsCA$1.13m0.48%
CA$ 75.2k
Ana Stegic
Executive Director of Clinical Operations3yrsCA$263.34k0.079%
CA$ 12.3k
Christina Cameron
Vice President of Investor Relationsno datageen gegevensgeen gegevens
Philip Stern
Vice President of Communicationsno datageen gegevensgeen gegevens

4.1yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ATE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).